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ABSTRACT
Estrogen-related receptor alpha (ERR1) is an orphan nuclear receptor that can
bind transcriptional co-activators constitutively. ERR1 expression correlates with
poor patient outcomes in breast cancer, heightening interest in this nuclear receptor
as a therapeutic target. Because ERR1 has no known regulatory ligand, a major
challenge in targeting its activity is to find cellular or synthetic modulators of its
function. We identified an interaction between ERR1 and KIF17, a kinesin-2 family
microtubule motor, in a yeast-2-hybrid screen. We confirmed the interaction using
in vitro biochemical assays and determined that binding is mediated by the ERR1
ligand-binding/AF2 domain and the KIF17 C-terminal tail. Expression of KIF17 tail
domain in either ER-negative or ER-positive breast cancer epithelial cells attenuated
nuclear accumulation of newly synthesized ERR1 and inhibited ERR1 transcriptional
activity. Conversely, ERR1 transcriptional activity was elevated significantly in KIF17
knock-out cells. Sequence analysis of the KIF17 tail domain revealed it contains
a nuclear receptor box with a conserved LXXLL motif found in transcriptional coactivators. Expression of a 12 amino-acid peptide containing this motif was sufficient
to inhibit ERR1 transcriptional activity and cell invasion, while deletion of this region
from the KIF17 tail resulted in increased ERR1 activity. Together, these data suggest
KIF17 modifies ERR1 function by two possible, non-exclusive mechanisms: (i) by
regulating nuclear-cytoplasmic distribution or (ii) by competing with transcriptional
co-activators for binding to ERR1. Thus targeting the ERR1-KIF17 interaction has
potential as a novel strategy for treating breast cancer.

INTRODUCTION

2]. ERR1 regulates transcription of its gene targets by
binding to specific ERR response elements (ERREs)
[3-5]. In addition, ERR1 can activate transcription
of estrogen receptor alpha (ER) target genes through
multiple, imperfect estrogen receptor response element
(ERE) half-sites, although this occurs primarily in cells

Estrogen related receptor alpha (ERR1) is an orphan
nuclear receptor that regulates genes involved in adaptive
energy and lipid metabolism, mitochondrial biogenesis,
osteogenesis, thermogenesis and ion homeostasis [1,
www.impactjournals.com/oncotarget
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lacking ER [4, 6-10]. ERR1 has a ligand binding pocket,
but no natural ligand has been identified to date and ERR1
can bind its coactivators constitutively [9, 11]. However,
ERR1 function can be modified in response to signaling
through EGF, ErbB2 and IGF-1R, which affect its binding
to co-activators and repressors, its transcriptional activity,
and its targeting for degradation [12-14]. ERR1 activity
may also be regulated by competition with ER for binding
to transcriptional co-factors, as it is known to modulate
responses to estrogen by competing with ER for binding
to EREs on target DNA and to regulatory co-activators or
co-repressors [15-17].
ERR1 expression correlates with poor prognoses in
breast cancer, particularly in patients with ER-negative,
ER-negative/ErbB2-positive, and triple-negative tumors.
As such, it has gained attention as a potent factor
and possible therapeutic target in treating aggressive
disease [18]. Small molecule, selective, inverse-agonists
occupy the ERR1 ligand binding domain and induce a
conformational change in ERR1 that inhibits binding of
ERR1 co-activators, leading ultimately to degradation
of ERR1 by the proteasome [19-22]. Importantly, ERR1
inverse agonists are effective in inhibiting orthotopic
breast tumor growth in murine models [23, 24]. To date
however, there is no evidence that these agents are in
clinical trial - perhaps because they would be predicted
to induce systemic toxicity in view of ERR1’s regulation
of genes in multiple essential pathways. Consequently, a
key step in development of clinically viable anti-ERR1
therapies is to identify cellular or synthetic modulators
that affect only subsets of ERR1-regulated genes that are
altered in the disease state.
We identified ERR1 as a binding partner of the
kinesin-2 family motor protein KIF17. Kinesins are
microtubule (MT) stimulated ATPases that transport a
variety of soluble and membrane-bound cargoes within the
cell [25, 26]. In humans, the kinesin family is comprised of
over 40 related proteins that share structural and functional
motifs. Kinesin motor domains are highly conserved and
bind MTs and ATP. Kinesin tail domains interact with
numerous cellular cargoes but are highly divergent,
contributing in large part to the uniqueness between family
members. Kinesins are known to participate in regulation
of transcriptional signaling [27-30], but their potential to
modulate nuclear receptor activity directly in breast cancer
has not been investigated. The studies described here show
that in ER-positive and ER-negative breast cancer cells,
ERR1 localization and activity can be regulated by KIF17.
Notably, a 12 amino acid peptide within the KIF17 tail
is necessary and sufficient to inhibit ERR1 function. This
peptide contains a conserved LXXLL nuclear receptor box
motif (NR box) found in nuclear receptor co-activators
[31-33]. The LXXLL co-activator motif is sufficient for
nuclear receptor (NR) binding. However, flanking amino
acids influence which of the many co-activators bind NRs
(e.g. in response to signaling); this affects expression
www.impactjournals.com/oncotarget

of distinct gene targets and likely downstream cellular
pathways [31-33]. The NR box in KIF17 shares features
with a subset of NR co-activators [31], suggesting that a
KIF17 peptide containing this NR box could be exploited
to inhibit a subset of ERR1-responsive genes. This could
lead to development of new therapeutic strategies targeting
ERR1 in breast and potentially other steroidogenic and
non-steroidogenic cancers.

RESULTS
ERR1 interacts with KIF17
We identified ERR1 as a binding partner of the
homodimeric kinesin-2 family motor KIF17 in a yeast2-hybrid screen of normal epithelial cells using the
KIF17 C-terminal tail domain as bait (KIF17-T, Figure
1A). Yeast-2-hybrid clones encoding the ligand-binding
and activator function-2 domains (LB/AF2) of ERR1
were the most abundant of twenty-three distinct hits in
iterative screening. We validated the interaction by coimmunoprecipitation using HEK-293 cells expressing
the yeast-2-hybrid bait and prey clones. We transfected
cells with myc-tagged KIF17-T and either GFP-tagged
ERR1-LB/AF2 or control GFP-empty vector (GFP-EV).
One day later we performed co-immunoprecipitation
analysis using anti-myc antibodies. In these experiments,
GFP-ERR1-LB/AF2, but not GFP-EV, co-precipitated
with myc-KIF17-T (Figure 1B). We next performed
endogenous co-immunoprecipitation experiments in
ER-positive MCF-7 breast cancer epithelial cells. Cell
lysates were incubated with non-specific control IgG or
with anti-ERR1 IgG and applied to protein-G sepharose
to isolate immune complexes. After separation by SDS
PAGE, immunoblot analysis confirmed that endogenous
KIF17 co-immunoprecipitated with ERR1 IgG, but not
non-specific IgG (Figure 1C). Co-immunoprecipitation of
endogenous ERR1 and KIF17 was also detected in ERnegative MDA-MB-231 cells (not shown). This interaction
may be transient, as significant KIF17 was found in nonbinding and wash fractions in these assays. Alternatively,
the relatively high level of unbound KIF17 may reflect
limiting amounts of ERR1 relative to KIF17.
To determine if the interaction between ERR1 and
KIF17 is selective, we next tested if KIF17-T interacts
with other ERR family members, and if ERR1 interacts
with other kinesin family members. ERR1 is one of three
ERR family members: ERR1, ERR2 (ERR beta) and
ERR3 (ERR gamma). ERR1 is expressed ubiquitously
while ERR3 has a more restricted tissue distribution [34,
35]. ERR2 expression is limited primarily to embryonic
tissues and we do not consider it further in these studies.
We co-transfected HEK-293 cells with cDNAs encoding
myc-KIF17-T and either GFP-ERR1 or GFP-ERR3.
50360

Oncotarget

Expression of KIF17-Tail inhibits ERR1
transcriptional activity in breast cancer cells

One day later we performed co-immunoprecipitation
analysis using anti-myc antibodies. Although ERR1 and
ERR3 share significant sequence identity in their LB/AF2
domains [36], GFP-ERR3 does not co-immunoprecipitate
with myc-KIF17-T (Figure 1D). Moreover, in parallel
experiments, we found that GFP-ERR1 does not interact
with the tail domain of the kinesin-3 family motor KIF1A
(myc-KIF1A-T) (Figure 1E). Consistent with this finding,
GFP-ERR1 from cell lysates was pulled down by purified,
recombinant GST-tagged KIF17-T and full-length KIF17
immobilized on glutathione-sepharose beads, but not by
GST-KIF1A-T (not shown). Together, these data show a
selective interaction between KIF17 and ERR1.

To determine if the interaction of KIF17 with
ERR1 has functional significance, we tested the effects of
expressing KIF17-T on ERR1 transcriptional activity in
ER-positive and ER-negative cells. MCF-7 (Figure 2A),
MDA-MB-231 (Figure 2B) or MCF-10a (not shown)
cells were co-transfected with the ERR1 responsive
element fused to luciferase (ERRE-Luc; [37]) and
mCherry-tagged KIF17-T (mCh-KIF17-T) or control,
empty vector (mCh-EV). Luminescence was measured

Figure 1: KIF17 interacts selectively with ERR1. A. Schematic diagrams of KIF17 and ERR1 and their interacting domains

identified in the yeast-2-hybrid screen. B. Co-immunoprecipitation of GFP-ERR1 LB/AF2 domain with myc-KIF17-tail in HEK293T
cells. Upper left lane shows the ~25kDa marker region where GFP migrates; upper right shows marker at 50kDa for GFP-ERR1-LBD/
AF2 migration. C. Co-immunoprecipitation of endogenous KIF17 and ERR1 from MCF7 cells. D. Co-immunoprecipitation analysis of
myc-KIF17-T and full-length GFP-ERR1 or GFP-ERR3 expressed in HEK-293T cells. Note that immunoprecipitated GFP-ERR1 routinely
migrates more slowly than the majority of total GFP-ERR1 detected in input lanes. E. Co-immunoprecipitation analysis of full-length GFPERR1 and myc-KIF17-T or myc-KIF1A-T expressed in HEK-293T cells. Inputs in D and E represents 10% of total lysate from HEK293T
cells expressing the indicated constructs. Asterisks in E show myc-tagged kinesin tails. Additional bands in the IP are IgG light chains.
www.impactjournals.com/oncotarget
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24 hours after transfection as a readout of transcriptional
activity. In control cells (mCh-EV, normalized to 100%),
luminescence signal was routinely robust. In cells
expressing mCh-KIF17-T, we measured a significant
reduction in luminescence when normalized to controls.
ERR1 and ER alpha share ~30% identity in their
LBD/AF2 domains [38], and ERR1 can activate a
subset of ER transcriptional targets using ER responsive
elements (ERE) [4, 6-10]. Considering this, we also tested
if KIF17-T interacts with and impacts ER transcriptional
activity, or if it is selective for ERR1. Co-expression of
KIF17-T with an ER reporter, ERE-Luc [39], had no effect

on luminescence in either ER-positive (Figure 2A) or ERnegative (Figure 2B) cell lines. In addition, ER did not coimmunoprecipitate with KIF17-T (not shown). These data
further show that the KIF17 tail acts on ERR1 selectively
and irrespective of ER status.
The above data demonstrate effects of an
overexpressed KIF17 fragment on ERR1. To determine if
KIF17 plays a physiological role in regulating ERR1, we
analyzed ERRE-Luc reporter activity in genome-edited,
KIF17 knock-out T84 human colon epithelial cells (KIF17/, Figure 2C). Wild-type T84 cells (KIF17+/+) and genome
edited cells were co-transfected with ERRE-Luc and

Figure 2: KIF17-Tail inhibits transcriptional activity of ERR1 on the ERRE, but not the ERE, in both ER-positive
and ER-negative breast cancer cells. Luciferase reporter assays showing transcriptional activity of endogenous ERR1 in A. MCF-7

and B. MDA-MB-231. C. Western blot for KIF17 in parental T84 cells (KIF17+/+) and T84 cells in which KIF17 was deleted by genome
editing (KIF17-/-). D. Luciferase reporter assay in T84 wild type and KIF17 knock-out cells expressing GFP-KIF17-T or control GFP-EV
and ERRE-Luc or ERE-Luc. Graphs show luminescence values normalized to GFP-EV. Error bars = SEM, ***p < 0.05. In panel D, GFPEV is also normalized to parental, KIF17+/+ cells. Error bars = SEM, ‡p < 0.05. Data is pooled from ≥ 3 experiments performed in triplicate.
www.impactjournals.com/oncotarget
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mCh-EV control or mCh-KIF17-T, and luminescence was
measured 24 hours later. In KIF17-/- cells co-expressing
mCh-EV, ERRE-Luc luminescence was elevated
significantly as compared with KIF17+/+ cells (Figure 2D).
Importantly, this increase was reversed when cells were
also co-transfected with mCh-KIF17-T, demonstrating that
the KIF17 tail domain can inhibit ERR1 activity in cells
lacking endogenous KIF17. Together, these data suggest
KIF17 acts as a repressor of ERR1 transcriptional activity.

expressing GFP-EV, KIF17-T reduced nuclear GFPERR1 by accumulation 25-35%. Because the KIF17tail encodes an NLS, a large fraction of mCh-KIF17-T
also accumulated in nuclei (Figure 3C, insets); this
likely impinges on the ability of expressed KIF17-T to
maximally inhibit ERR1 nuclear translocation in these
assays. Despite this limitation, our results suggest that one
way the KIF17 tail affects ERR1 transcriptional function
is by inhibiting its accumulation in the nucleus.
If KIF17 acts as an active transporter of ERR1 we
would expect ERR1 nuclear accumulation to be dependent
on an intact MT array. To test this, we treated cells with
the MT depolymerizing agent nocodazole (NZ; 33µM)
immediately following cDNA injection. NZ treatment
accelerated the accumulation of nuclear GFP-ERR1
in all cells at early time points of the recording, but did
not alter the final proportion of nuclear:total GFP-ERR1
in cells expressing either mCh-EV or mCh-KIF17-T
(Figure 3C, Table). This suggests KIF17-T affects nuclear
translocation of ERR1 by sequestering it on MTs and
is consistent with data showing that purified KIF17Tail can bind MTs in vitro [43]. Interestingly, although
nuclear accumulation of ERR1 was not inhibited by MT
depolymerization, expression of the KIF17-T still inhibited
ERR1 transcriptional activity in luciferase reporter assays
under these conditions (Figure 3D). From these data, we
conclude that the KIF17 Tail domain can inhibit ERR1
function in the nuclear compartment, independent of MTs.

Expression of KIF17-Tail inhibits nuclear
translocation of ERR1 in breast cancer cells
Immunofluorescence analysis of endogenous ERR1
and KIF17 in ER-positive and ER-negative cells showed
that ERR1 and KIF17 localized in the cytoplasm and
nucleus (Figure 3A, upper panels). KIF17 also localized
on MTs, as expected for a MT-associated motor and as
described previously [40], and nuclear KIF17 was not
unexpected as it contains a nuclear localization signal
(NLS) in its C-terminal tail (see Figure 4A and [41]).
Although cytoplasmic KIF17 and ERR1 puncta were
numerous, we only measured a significant colocalization
between the two proteins when we analyzed their
distributions specifically along MTs. Line-scan analysis
of ERR1 and KIF17 along MTs (Figure 3A, lower panels,
graph and table) revealed that 37% of ERR1 puncta
colocalized with KIF17, as compared with 18% measured
after shifting the KIF17 image by 5 pixels to detect
random co-distribution.
Kinesin-tail domains often have dominant-negative
effects on protein translocation when overexpressed in
cells, as they bind cargo but do not move on MTs [25,
42]. Because a portion of cytoplasmic ERR1 colocalized
with KIF17 on MTs, we tested if expression of KIF17-T
affected translocation of ERR1 from the cytoplasm to
the nucleus. We expressed GFP-ERR1 in cells acutely
by cDNA injection and monitored newly synthesized
protein by time-lapse fluorescence microscopy (Figure
3B). ER-positive and ER-negative cells were injected
with GFP-ERR1 and mCh-EV or mCh-KIF17-T cDNAs
and incubated for 90 minutes to allow for protein
expression. Cells were then transferred to a temperaturecontrolled chamber on the microscope and imaged live at
10min intervals for 180min. After image acquisition, we
quantified GFP-ERR1 fluorescence in individual cells and
cell nuclei and determined the ratio of nuclear:total GFP
(N/T) per cell over time (Figure 3B and Table in 3C). At
the start of recordings, most GFP-ERR1 localized to the
cytoplasm with only ~15-25% in the nucleus in MCF7 and MCF-10a cells (Figure 3C). In control cells coexpressing mCh-EV, ~40-50% of GFP-ERR1 localized to
the nucleus 3h later. By contrast, in cells co-expressing
mCh-KIF17-T, only ~30% of GFP-ERR1 localized in
the nuclear compartment. Thus relative to control cells
www.impactjournals.com/oncotarget

A KIF17-Tail peptide containing an LXXLL NR
box motif is necessary and sufficient to inhibit
ERR1-mediated transcription
To more fully characterize how KIF17 interacts with
ERR1 and to further explore the mechanism by which
it affects ERR1 function, we analyzed the amino acid
sequence of the KIF17 tail domain. We identified a nuclear
receptor box (NR box) motif comprised of LXXLL
residues near the N-terminal region of KIF17-T (Figure
4A). The LXXLL motif is found in nuclear receptor coactivators and mediates their binding to nuclear receptors
[31-33]. To determine if this LXXLL motif is necessary
for inhibition of ERR1 by KIF17-T, we generated an
N-terminal truncation mutant in which 12 amino acids,
inclusive of the NR box, were removed from KIF17-T
(KIF17-TΔNR, underlined amino acids were deleted, Figure
4A). We co-expressed GFP-KIF17-TΔNR and ERRE-Luc
in ER-positive and ER-negative cells and measured
luminescence 24h after transfection. Unlike wild-type
KIF17-T, KIF17-TΔNR did not inhibit ERR1 transcriptional
activity, and instead amplified transcription relative to
controls (Figure 4C). Interestingly, we found that mycKIF17-TΔNR co-immunoprecipitated with GFP-ERR1
(Figure 4B), albeit less efficiently, and that expression of
KIF17-TΔNR attenuated ERR1 nuclear accumulation to the
50363
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Figure 3: KIF17-Tail attenuates nuclear accumulation of ERR1 in both ER-positive and ER-negative breast cancer
cells. A. Upper panels: Localization of endogenous ERR1 (red) and KIF17 (green) in MCF7 (left panel) and MCF10a (right panel) cells.
Lower panels: Localization of ERR1, KIF17 and MTs (cyan) in MCF-7 cells. ERR1 signal in this image was attenuated by modifying
the LUT so that the MT array could be more easily visualized. The ROI indicated in this panel showing the entire cell is magnified in
the right panel to highlight ERR1 and KIF17 along individual MTs. Graph and table show line-scan and quantification of ERR1 and
KIF17 fluorescence intensities over a 10µm length of an individual MT. Solid circles on the image show overlapping fluorescence peaks
on the line-scan. Dashed circles show other overlapping puncta on different MTs that are not represented in the line-scan. N = 63 MTs
analyzed. B. Schematic describing the experimental protocol used for time-lapse imaging of GFP-ERR1 nuclear accumulation. Images
show representative cells expressing GFP-ERR1 after cDNA injection in the first (t0) and last (t180) frames of a time-lapse in MCF-7 cells.
After image acquisition, regions of interest were drawn defining individual cells (yellow outline) and nuclear boundaries (blue outline) at
the first and last time points. GFP integrated fluorescence intensities were measured and the ratio of Nuclear/Total (N/T) GFP-ERR1 was
calculated. C. MCF-7 cells injected with GFP-ERR1 and mCh-KIF17-T or control, mCh-EV cDNAs. Images show GFP-ERR1 in first and
last frames of time-lapse recordings. Insets: mCh-EV control and mCh-KIF17-T in injected cells. Table: pooled data from 3 experiments
reporting (i) % nuclear GFP-ERR1 at indicated times, (ii) the change in % nuclear fluorescence (∆N/T), and (iii) the % inhibition of
nuclear accumulation by expression of KIF17-T. D. Luminescence measured in untreated and NZ-treated MCF7 and MDA-MB-231 cells
expressing ERRE-Luc and GFP-KIF17-T or control GFP-EV. Graphs show normalized luminescence values pooled from ≥ 3 experiments
performed in triplicate. Error bars = SEM. *** p < 0.05. Scale bars = 25μm unless otherwise noted.
www.impactjournals.com/oncotarget
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Figure 4: A 12 amino acid peptide in the KIF17-Tail is necessary and sufficient to inhibit ERR1 transcriptional activity.
A. Sequence of the KIF17-Tail. The 12 amino acid NR box peptide containing the LXXLL motif is underlined. B. Co-immunoprecipitation
of GFP-ERR1 with myc-EV control, myc-KIF17-T or myc-KIF17TΔNR expressed in HEK293 cells. Immunoprecipitates and total lysates
were analyzed by immunoblot using anti-GFP and anti-myc IgG. C., D. Luciferase reporter assays showing transcriptional activity of
endogenous ERR1 in MCF7 cells expressing ERRE-Luc and myc-EV, myc-KIF17-T, myc-KIF17ΔNR (panel C) or myc-KIF17NR (panel
D). E. Luciferase reporter assays showing transcriptional activity of endogenous ERR1 in parental LM2 and LM2NR cells transfected with
ERRE-Luc. F. Same as in panel E, but comparing cells transfected with control or ERR1 siRNAs. Graphs show normalized luminescence
values pooled from ≥ 3 experiments performed in triplicate. Error = SEM. ***p < 0.05.
www.impactjournals.com/oncotarget
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same extent as KIF17-T (not shown). Thus these 12 amino
acids are not required for binding of KIF17-T to ERR1,
but are necessary to modify ERR1activity. Considered
together, these data suggest additional sequences in the
KIF17-Tail domain contribute to ERR1 binding, and
that the effects of KIF17 on ERR1 function are mediated
primarily through interaction of the KIF17 NR box motif
with ERR1 in the nuclear compartment.
To determine if this LXXLL-containing peptide
in KIF17-Tail is sufficient to inhibit ERR1 function, we
generated expression constructs encoding only these 12
amino acids (KIF17-TNR, underlined amino acids, Figure
4A). We co-expressed ERRE-Luc and GFP-KIF17TNR in ER-positive and ER-negative cells and measured
luminescence 24h after transfection. KIF17-TNR inhibited
ERR1-mediated transcription, like wild-type KIF17-T, as
compared with cells co-expressing empty vector controls
(Figure 4D). Expression of myc-tagged KIF17-TNR was
equally effective in reducing luminescence, showing that
the GFP moiety does not interfere with peptide activity
(data not shown).
We also generated a cell line stably expressing
GFP-KIF17-TNR peptide at lower levels than in transiently
transfected cells, which we use in tests of the physiological
consequences of KIF17-mediated modulation of ERR1
(see below). Stable transfectants were produced in the
highly invasive MDA-MB-LM2 cell line [44] and are
denoted LM2NR henceforth. Analysis of luciferase activity
in parental LM2 and LM2NR cells 24hr after transfecting
ERRE-Luc showed that luminescence was significantly
lower in LM2NR as compared with control LM2 cells
(Figure 4E). We measured a similar reduction in luciferase
activity using LM2 cells stably expressing GFP-KIF17-T
(not shown). Importantly, the reduction in ERRE-Luc
activity measured in LM2NR cells was similar in LM2
parental cells depleted of ERR1 by siRNA-mediated
knock-down; ERR1 depletion in LM2NR cells did not result
in further reduction of luciferase activity (Figure 4F). This
finding suggests that the remaining transcriptional activity
measured in these cultures is likely due to the activity of
ERR3, which also binds the ERRE [10] and is consistent
with our finding that the KIF17-Tail does not interact
with ERR3. Together, these data show that a KIF17-Tail
dodeca-peptide containing an NR box motif is necessary
and sufficient to inhibit ERR1-mediated transcription.

of previously described ERR1 targets [6], we found that
stable expression of GFP-KIF17-T or GFP-KIF17NR
significantly reduced transcription of ERR1 and HIF1A,
but not osteopontin, aromatase, PGC1A or TFF-1 (Figure
5A). As expected in the case of HIF1A suppression, a
preliminary differential RNAseq analysis of LM2NR and
control LM2 cells (not shown) also revealed attenuated
expression of ICAM-1 and angiopoietins, which are
regulated by HIF1A [45]. Consistent with the lack of
change in PGC1A, a key co-activator of genes involved
in mitochondrial biogenesis and function, we observed
no differences in mitochondrial mass or function in
fluorescence-based assays (not shown), nor did we detect
significant changes in mitochondrial genes by RNAseq in
LM2 NR cells. Thus the KIF17-Tail domain and the KIF17
NR box motif peptide inhibit transcription of a subset of
known ERR1 targets.
Stable expression of GFP-KIF17-T or GFP-KIF17NR
in LM2 cells also significantly inhibited transcription
of Claudin-4, 14-3-3ζ/δ, and presenilin (Figure 5A),
potentially new ERR1 targets we identified as downregulated in LM2NR cells by RNAseq analysis (not shown).
Whether these represent bona fide ERR1 transcriptional
targets is not yet clear and will be determined directly by
ChIPseq in follow-up studies. Claudin-4 and 14-3-3δ/ζ,
are of particular interest in the breast cancer landscape.
High expression of claudin-4 in primary tumors, and
particularly in distant metastases, is a negative prognostic
indicator in ER(-) and triple-negative breast cancer
patients and is a powerful predictor of survival [46-50].
High expression of 14-3-3δ/ζ is a negative prognostic
biomarker associated with tamoxifen resistance in ER+
patients [51-53]. Identifying potential ways to modulate
their expression could reveal additional cancer treatment
modalities.
To determine the consequences of KIF17 mediated
modulation of ERR1 transcriptional targets on cell
behavior, we performed trans-well invasion and 2D
migration assays with parental LM2 and LM2NR cells. For
invasion assays, serum-starved cells were seeded in serumfree medium on the upper surface of Matrigel-coated
trans-well filters with 8µM pores. Complete medium
containing 5% FBS was added to the lower chamber and
cultures were incubated 10h before fixation and analysis
of cells that had invaded the Matrigel and emerged on
the bottom surface of the filter. Invasion of LM2NR cells
was significantly impaired as compared with parental
LM2 cells (Figure 5B). These results are consistent with
reduced invasion observed with siRNA mediated knockdown of ERR1 levels seen in multiple different cell types
[54]. For analysis of migration in 2D, monolayer cells
were scratch-wounded and cell migration/wound closure
was monitored by time-lapse imaging over a 6h period.
We measured no significant differences in cell migration
rate and extent of wound closure between parental LM2
and LM2NR cells (Figure 5C). This contrasts reports that

The KIF17 NR box motif attenuates ERR1
transcriptional activity selectively and inhibits cell
invasion through matrigel
To determine if expression KIF17-T or KIF17-TNR
affects the transcription of known and potentially new
ERR1 targets, we performed qPCR using RNA isolated
from control LM2 cells stably expressing GFP-empty
plasmid, LM2NR and LM2-KIF17-T cells. In our analysis
www.impactjournals.com/oncotarget
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depletion of ERR1 with siRNA inhibits both cell invasion
(3D) and migration (2D) [54] and likely reflects selective
effects of expressing KIF17-TNR on the ability of LM2NR

cells to degrade extracellular matrix. Thus inhibition of
ERR1 activity with the KIF17 tail NR box peptide does
not globally affect cellular processes associated with

Figure 5: Stable expression of KIF17NR or KIF17-Tail in LM2 cells attenuates transcription of a subset of ERR1
targets and inhibits invasion through materiel. A. qPCR analysis of known and possible new ERR1 targets in LM2, LM2NR and

LM2-KIF17-Tail cells. Error = SEM. ***p < 0.0005, **p < 0.005, *p < 0.05. B. Trans-well Matrigel invasion of parental LM2 and LM2NR
cells. Images show representative regions of invaded cells. Graph shows fold change in invasion compared to parental LM2 cells and are
pooled from duplicate samples from ≥ 3 experiments. Error bars = SEM. ***p < 0.05. Scale bar = 25µm. C. Cell migration into a wound
by LM2 and LM2NR cells. Solid lines show the cell front at the first time point. Dotted lines show the cell front in the final frame of the
time-lapse (t = 6hrs). Scale bar = 50µm. Images are representative of cell migration in 6 random fields over time. Graph shows pooled data
from ≥ 3 experiments. Error bars = SEM.
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downstream outputs of ERR1 transcription. This finding
also highlights the potential of this peptide as a selective
inhibitor of ERR1 regulated cell behaviors.

in KIF17-/- cells, and that re-expression of the KIF17
tail domain is sufficient to reduce ERR1 activity back to
normal levels measured in wild-type KIF17+/+ cells further
indicates that this kinesin has a physiologically relevant
function in modulating ERR1-mediated transcription.
Cumulatively, our data lead us to propose a model
in which KIF17 can modulate ERR1 by two possible,
non-exclusive mechanisms: by controlling the nuclearcytoplasmic distribution of ERR1 and by acting as a
repressor of ERR1-mediated transcription in the nucleus
(Figure 6). This idea is supported by data showing that
(i) endogenous KIF17 (and expressed KIF17 or KIF17Tail) localizes to both the cytoplasmic and nuclear

DISCUSSION
The data presented here document a previously
unreported interaction between the kinesin KIF17 and
the orphan nuclear receptor ERR1 and suggest KIF17
plays a selective, regulatory role in modulating ERR1
transcriptional activity and downstream cellular behaviors
associated with expression of ERR1 target genes. Our
data showing that ERR1 activity is elevated significantly

Figure 6: Proposed model of KIF17-mediated regulation of ERR1. Endogenous KIF17, expressed KIF17-FL, or KIF17-Tail in

the cytoplasmic compartment could impact ERR1 function by sequestering ERR1 on MTs in the cytoplasm. In the nuclear compartment,
endogenous KIF17, expressed KIF17-FL, KIF17-Tail or KIF17-TNR could impact ERR1 function by competing with transcriptional
coactivators for binding to ERR1. KIF17∆NR lacking the NR box motif binds ERR1 but does not inhibit its activity; thus the NR box is
necessary for KIF17-mediated modulation of ERR1 nuclear function.
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compartments and (ii) over-expressed KIF17-Tail
attenuates nuclear accumulation of newly synthesized
ERR1 and inhibits ERR1 transcriptional activity in
cells with or without an intact MT network. Several
reports show that kinesins, including the testis specific
isoform of KIF17 (KIF17b), can bind and sequester
transcriptional regulators in the cytoplasm as a way to
modify transcriptional signaling [27, 30, 55, 56]. An intact
MT network is needed for the sequestration function of
these kinesins, but MT-stimulated, kinesin ATPase activity
is not, demonstrating that these motors participate in
transcriptional regulation by acting as cytoplasmic tethers
rather than active transporters. Protein tethering on MTs
represents a potentially effective way to insure proper
temporal and spatial control of regulated transcription
pathways as MTs are the major cellular highways for longdistance transport and can facilitate productive encounters
between signaling pathway molecules at discrete locations
in cells. MT motors can also impact transcription by
acting in their capacity as transporters, and this has been
well documented in the case of cytoplasmic dynein,
another class of MT-associated motor, which delivers
its transcription factor cargoes to the nucleus for import
[57-60]. Because we find that inhibition of ERR1 nuclear
accumulation by KIF17-Tail requires intact MTs, we
envision KIF17 most likely impacts ERR1 localization by
acting as a MT tether. In addition, the KIF17 tail alone
is not competent to move on MTs, but it can bind MTs
in vitro independent of its canonical N-terminal, MTbinding and motor domain [43]. As such, its ability to
inhibit ERR1 nuclear accumulation in our assays was not
unexpected and further supports the idea that KIF17 can
act in part as a cytoplasmic tethering factor for ERR1.
KIF17 could also affect ERR1 transcriptional
activity by repressing its function within the nuclear
compartment. This idea is bolstered by our finding that,
in addition to an NLS, the KIF17 tail domain contains a
conserved LXXLL NR box motif found in transcriptional
co-activators. Transcriptional co-factors regulate binding
of ERR1 to ERREs on target gene DNA [61, 62]. For
canonical NRs, ligand binding induces a conformational
change that accommodates the NR box motifs coactivators [33]. Distinctive NR box-flanking residues
classify co-activators into three general categories and
mediate recognition of additional NR structural features
that impact their binding to specific NRs in response to
diverse signaling pathways [33, 61]. Unlike canonical
NRs, ERR1 and other orphans interact with co-regulators
in a ligand-independent manner and thus can affect
transcription constitutively [9, 11]. However, ERR1coactivator interactions are regulated by competitive
binding at co-activator sites, and by signal-mediated
post-translational modifications that affect co-activator
affinity for ERR1 [12, 13, 17, 22, 63-65]. Here, we
show that a 12 amino acid KIF17 NR box peptide is
necessary and sufficient to inhibit ERR1 activity. It is also
www.impactjournals.com/oncotarget

sufficient to inhibit invasive behavior of breast cancer
cells. This peptide bears signatures of NR co-activators
with hydrophobic amino acids at the -1 position relative
to LXXLL [31, 33]. Interestingly, deletion of the KIF17
NR box peptide does not affect binding of the KIF17Tail to ERR1 and expression of KIF17-T∆NR results in
increased ERR1 activity. This is an unexpected result
and we speculate that removal of the KIF17 NR peptide
allows ERR1 to access additional factors which enhance
its function. Together, these data suggest KIF17 inhibits
nuclear functions of ERR1 by competing with coactivators for ERR1 binding.
ER-negative breast tumors are resistant to
chemotherapeutics targeting ER and estrogen production,
and this resistance is partially attributable to ligandindependent activities of ERR1, loss of ER-mediated
competition for regulatory cofactors, and the ability of
ERR1 to stimulate ER target genes independently of
ER, particularly in the breast cancer landscape [6]. The
association of high ERR1 levels with poor prognoses,
particularly in ER-negative/ErbB2(+) and triple-negative
breast cancer, has heightened interest in targeting ERR1
and its modulators pharmacologically in breast and
other steroidogenic cancers [66, 67]. Inverse agonists
that interact with ERR1 have been identified and, like
ERR1 silencing, they retard orthotopic tumor growth
and inhibit migration of breast cancer cells in culture
[16, 23, 24]. Mechanistically, these compounds interact
with ERR1 in its predicted, but physiologically unused
ligand binding domain, inducing a conformational change
that inhibits co-activator binding, and leads ultimately
to ERR1 degradation by the proteasome [20-22, 68]. To
our knowledge however, none of these inhibitors are in
clinical trial; most likely this is because they are predicted
to induce systemic toxicity considering ERR1’s control
of genes in multiple, essential pathways. Attractive
alternative therapeutics would modify co-factor binding
selectively, and could be tailored to affect only the subset
of ERR1 targets altered in the disease state. The selective
effects of expressing the KIF17-Tail or KIF17 NR-box
peptide on expression of known, and possibly new, ERR1
targets suggest a KIF17-based treatment modality could be
exploited in such a manner.
The data presented here document a new mechanism
to regulate ERR1 activity in breast cancer cells and reveal
a new and direct mode by which kinesins can impact
transcription. Our findings support a hypothesis that
KIF17-ERR1 interactions could be exploited to selectively
inhibit subsets of ERR1 targets and down-stream cellular
processes. Notably, the ability the LXXLL-containing
KIF17 NR box peptide to inhibit ERR1 transcriptional
activity suggests it could be used, with or without
additional modification, as a tool to attenuate ERR1
function in breast cancer. In the future, it will be important
to determine the effects of altering LXXLL flanking
sequences on transcriptional outputs of ERR1 action. It
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will also be interesting to determine if additional kinesins
are engaged similarly to regulate ERR1 and other NRs.

CTC CCA GGA GCG TGA CTC CAT GC and reverse;
GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC
CAG GAG CTG CTG CAA GAG C-3’. ERR3: forward;
5’- GGG GAC AAG TTT GTA CAA AAA GCA GGC
TCC ATG TCA AAC AAA GAT CGA C and reverse;
GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC
GAC CTT GGC CTC CAA CAT T-3’. The KIF17-Tail and
KIF1A-Tail constructs were described previously [40],
[69]. ERR1: forward; 5’ - GTA CAA AAA AGC AGG
CTT CTC CAG GGA GGT GGT GGG C and reverse;
GTA CAA GAA AGC TGG GTC TCA GTC CAT CAT
GGC CTC GAG. ERRE-Luc reporter was provided by JM
Vanacker (University of Lyon, France). 3X-ERE-Luc was
purchased from Addgene (Plasmid 11354). All constructs
were verified by sequencing prior to use in experiments.

MATERIALS AND METHODS
Cell culture, transfection, and microinjection
MCF7, MDA-MB-231, MDA-MB-LM2 (LM2) and
HEK293T cells (ATCC) were cultured in DMEM (4.5 g/
liter glucose) with 10% FBS and 20 mM Hepes, pH 7.2.
MCF10a cells were cultured in DMEM:F12 50/50 with
5% FBS, 0.5mg/mL hydrocortisone, 100ng/mL cholera
toxin and 20ng/mL EGF. MCF-7, MCF-10A, MDAMB-231 and LM2 cells were transfected with 10µg DNA
using the AmaxaTM nucleofector (Lonza) as recommended.
HEK293T cells were transfected using JetPrimeTM
(Polyplus Transfection, Illkirch, France) as recommended.
Microinjection was performed as described [40]. Briefly,
5-20 µg/ml cDNAs in HKCl (10 mM Hepes, 140 mM
KCl, pH 7.4) were pressure injected into cell nuclei using
a micromanipulator (MMO-202ND; Narishige). Cells
were incubated at 37°C for 90min to allow for expression
of cDNAs.

Knock-down of ERRA by siRNA
5µg siRNA was transfected into cells using AMAXA
electroporation and ERRA levels were monitored by
western blot. Cells were harvested 3 days after transfection
and used in luciferase reporter assays. ERRA siRNAs used
targeted sense strand 5’ GAG CAU CCC AGG CUU CUC
AUT T and antisense strand AUG AGA AGC CUG GGA
UGC UCT T 3’ and have been described previously [70,
71]. Scrambled siRNA was used as a control.

Generation of stable cell lines

Yeast 2-hybrid

LM2NR cells were generated by transfecting LM2
cells with GFP-KIF17-TNR followed by sorting using the
FACSAria II cell sorter (BD Biosciences). Transfected cell
populations were maintained in media containing 2μg/mL
of G418 during the first two rounds of cell sorting, after
which G418 was omitted. Genome-edited, KIF17 knockout T84 cells were generated by transfecting plasmids
designed for genome-wide, Cas9-mediated knock-out
of human KIF17 (KN209079, OriGene). Cells were
passaged once and subjected to puromycin selection (6μg/
mL) for one week. Individual puromycin-resistant clones
were selected using cloning rings and expanded. KIF17
knock-out was determined in each clone by Western blot.
Experiments were performed in two of the KIF17-/- clonal
cell lines.

A yeast-2-hybrid library from normal colon
epithelial cells (25µg) was screened using the C-terminal
tail domain of KIF17 as bait as described previously [72].
7.2 x 106 clones were analyzed with 432 positives detected.
Clones detected in iterative rounds of screening were
used as PCR templates to prepare tagged, mammalian
expression constructs for further analysis. We confirmed
that clones encoding a.a. 254-423 of ERR1 interacted
with KIF17 tail domain by co-immunoprecipitation in
transfected HEK-293 cells.

Immunoblotting and co-immunoprecipitation
Immunoprecipitation of expressed proteins was
performed using lysates from HEK293 cells transfected
with indicated constructs. One day after transfection,
cells were lysed in lysis buffer (50mM HEPES, pH 7.4
containing, 150mM NaCl, 1.5mM MgCl2, 0.5mM CaCl2,
10% (v/v) glycerol, 1% (v/v) Triton-X100, 1mM PMSF,
and 0.5mg/ml each of leupeptin, bestatin, pepstatin)
with rocking for 30 minutes. Lysates were cleared using
Protein-G sepharose beads (GE Healthcare) and incubated
overnight with 6-8μg rabbit anti-GFP antibody (Novus
Biologicals, NB 600-303) or mouse anti-myc antibody
(Sigma M4439). Immunoprecipitation of endogenous

Expression constructs
KIF17-TΔNR, KIF17-TNR peptide, ERR1 and ERR3
were amplified by PCR from human Caco2 cells and
cloned into GatewayTM expression vectors (Invitrogen).
Primers: KIF17-TΔNR: forward; 5’-GGG GAC AAG TTT
GTA CAA AAA AGC AGG CTC CGA GCA GGT GCA
GCC CCT GAT TC and reverse; GGG GAC CAC TTT
GTA CAA GAA AGC TGG GTC TCA CAG AGG CTC
ACT GCC AAA GTT-3’. KIF17-TNR peptide: forward;
5’-GGG GAC AAG TTT GTA CAA AAA AGC AGG
www.impactjournals.com/oncotarget
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protein was performed using MCF-7 cells. Cells were
grown to confluence and lysed for 30 minutes. Lysates
were cleared using Protein-G sepharose and incubated
overnight with 10μg mouse anti-ERR1 antibody (Abcam
ab418618). Other primary antibodies include mouse antiGFP (Roche, 1814460), rabbit anti-myc (Cell Signaling,
2276S), goat anti-ERRα (Santa Cruz Biotechnology, sc32971) and goat anti-KIF17 IgG (M20, Santa Cruz).

objective or a 20x (NA 0.5) plan fluor, phase contrast
objective and images were collected with a Neo sCMOS
camera as described above.
Nuclear translocation of GFP-ERR1
Following
image
collection,
background
fluorescence was subtracted from 16-bit images. Regions
of interest (ROIs) were drawn after morphometric
thresholding around individual cells and their
corresponding nuclei. Integrated florescence intensities
were calculated for nuclear ROI (N) and total ROI (T) and
expressed as a ratio, N/T, per individual cell over time.
Average N/T per cell at the start and end time points were
plotted using Graphpad Prism 5. For MT depolymerization
experiments, cells were treated with 33µM nocodazole
(NZ) immediately following cDNA injection and cells
were maintained in NZ for the duration of the experiment.

Luciferase reporter assays
24h after transfection cells were washed with PBS
and lysed using Glo-lysis buffer (Promega) for 5min.
Lysates were collected and mixed 1:1 with BrightGlo
Luciferase assay reagent (Promega) and luminescence
measured using a Luminometer (Synergy H1, BioTek).
For MT depolymerization experiments, cells were treated
with 33µM nocodazole for 270 minutes before addition of
Glo-lysis buffer. Results were corrected for background
luminescence and plotted using GraphPad Prism 5.
Statistical significance, p < 0.05, was determined using
Bonferroni analysis.

Cell migration
Cells were grown on cover slips until a monolayer
was formed and wounded using a sterile pipette. Timelapse recordings were started 3h after wounding, with
images acquired at 10m intervals for a duration of 6 hours.
Images were thresholded to define the wound area, which
was quantified using Nikon Elements software. Results
were plotted Graphpad Prism 5.

Immunofluorescence
Cells were fixed in −20°C methanol for 1-2 min.
Microtubules were detected using YL1/2 rat-antityrosinated tubulin (J. Kilmartin). KIF17 was detected
with rabbit anti-KIF17 IgG (Sigma, K3638). ERR1 was
detected with goat anti-ERR1 IgG (Santa Cruz, sc-32971).
Fluorescently conjugated secondary antibodies were
from Jackson ImmunoResearch. Images were acquired
with a Neo sCMOS camera (6.45µm pixels, 560MHz,
Andor Technology) on a Nikon TiE inverted microscope
(Nikon Inc., Mellville, NY) using 40X (NA 1.0) or 60X
(NA 1.4) plan apochromat oil immersion objectives. 1416bit images were scaled linearly to highlight features of
interest and converted to 8-bit copies for figure assembly.
Devices were controlled by Elements software (Nikon
Instruments). Line-scan analysis: The number of ERR1
and KIF17 puncta on MTs, and their colocalization shown
in Figure 4A, was determined by line-scan analysis
of fluorescence intensities along 10µm of individual
MTs. Overlapping fluorescence peaks were scored as
colocalized puncta.

Trans-well invasion assay
Matrigel™ Invasion Chambers (Corning, part
#354480) were hydrated overnight in serum-free DMEM.
Cells were trypsinized, resuspended in serum-free DMEM
and counted. 2x105 cells were added to the upper chamber
in serum-free DMEM. DMEM with 5% FBS, or serumfree DMEM as a control, was added to the lower chamber.
Duplicate samples for each condition were analyzed in 3
independent experiments. Cells were incubated at 37°C
for 10hrs. Following incubation, media was aspirated
carefully, cells were fixed in 4% paraformaldehyde for
5 minutes and stained using 0.05% crystal violet for 5
minutes. Membranes were washed, excess Matrigel and
cells remaining in the upper chamber were removed using
low-lint G-tip swabs. Filters were dried, excised from the
inserts and mounted onto slides for imaging. 6 x 2.3mm2
fields per membrane were imaged using a 10x (0.3 NA)
plan fluor objective. Cells stained with crystal violet were
outlined by morphometric thresholding and counted using
Nikon Elements software. Unusually large cell clusters/
clumps were excluded from the analysis. Results were
plotted using Graphpad Prism 5.

Time-lapse imaging and analysis
For time-lapse imaging, cells were transferred to
recording medium (Hanks balanced salt solution with 20
mM Hepes, 1% FBS, 4.5 g/liter glucose, essential and
nonessential amino acids) and incubated at 37°C in a
thermal-controlled chamber (Harvard Apparatus) on the
microscope. Time-lapse images were acquired at 10min
intervals for 3h using a 20x (NA 0.75) plan apochromat
www.impactjournals.com/oncotarget

qRT-PCR
qRT-PCR was performed on a Taqman 7900HT
using standard methods. Total RNA and cDNA was
obtained from stable cell lines using Qiagen RNAeasy
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RNA extraction kit and cDNA generated using standard
methods. GAPDH was used as a control. All primers
were obtained from Integrated DNA Technologies. TET/
ZEN/IBFQ was used as the dye-quencher on probes
for GAPDH. 6-FAM/ZEN/IBFQ was used as the dyequencher for all other primers. The following primers were
used. ERR1: Forward 5’ CTA TGG TGT GGC ATC CTG
TG 3’ and reverse TCT CCG CTT GGT GAT CTC A 3’
and , Osteopontin: Forward 5’ CCC CAC AGT AGA CAC
ATA TGA TG and reverse TTC AAC TCC TCG CTT TCC
AT 3’, Aromatase: Forward 5’ AGA GGA AAC ACT CAT
TAT CAG CA and reverse GCC TTT CTC ATG CAT ACC
GAT 3’, Presenilin: Forward 5’ TCC CTT GAC TGG CTA
CCC and reverse CCA GCA CAC TGT AGA AGA TGA
3’, 14-3-3 ζ/δ:Forward 5’ GCA TGA AGT CTG TAA CTG
AGC A and reverse GCA CCT TCC GTC TTT TGT TC
3’, Claudin-4: Forward 5’ CCA TAT AAC TGC TCA ACC
TGT CC and reverse AGA TAA AGC CAG TCC TGA
TGC 3’, GAPDH: Forward 5’ ACA TCG CTC AGA CAC
CAT G and reverse TGT AGT TGA GGT CAA TGA AGG
G 3’, HIF2: Forward 5’ AGC CTA TGA ATT CTA CCA
TGC G and reverse CTT TGC GAG CAT CCG GTA 3’ ,
TFF1: Forward 5’ CCA TGG AGA ACA AGG TGA TCT
and reverse TGA CAC CAG GAA AAC CAC AA 3’ ’,
HIF1A: Forward 5’ CTC TGA TCA TCT GAC CAA AAC
TCA and reverse CAA CCC AGA CAT ATC CAC CTC
3’ , PGC1A (exon 8-9): Forward 5’ GTC CTT TTC TCG
ACA CAG GT and reverse GTC TGT AGT GGC TTG
ACT CAT AG 3’ , PGC1A (exon 1-2): Forward 5’ GAG
TCT GTA TGG AGT GAC ATC G and reverse TGT CTG
TAT CCA AGT CGT TCA C 3’ .
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